STOCK TITAN

Tharimmune Board Member Buys Company Stock: What Investors Should Know

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Form 4 filing reveals that Sanam Parikh, Director of Tharimmune (THAR), executed a direct purchase of company shares on June 20, 2025. The insider transaction details:

  • Acquired 1,000 shares of Common Stock at $1.45 per share
  • Total transaction value: $1,450
  • Following the purchase, Parikh now holds 1,770 shares directly

This insider buying activity by a board member could signal confidence in the company's future prospects. The transaction was reported within the required filing window, with the Form 4 being signed on June 23, 2025. No derivative securities were involved in this transaction.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parikh Sanam

(Last) (First) (Middle)
C/O THARIMMUNE, INC.
34 SHREWSBURY AVENUE

(Street)
RED BANK NJ 07701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 P 1,000 A $1.45 1,770 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Sanam Parikh 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of THAR stock did Director Sanam Parikh purchase on June 20, 2025?

According to the Form 4 filing, Director Sanam Parikh purchased 1,000 shares of THAR common stock on June 20, 2025 at a price of $1.45 per share.

What is the total number of THAR shares owned by Sanam Parikh after the June 2025 purchase?

Following the reported transaction, Sanam Parikh directly owned 1,770 shares of Tharimmune, Inc. (THAR) common stock.

What was the purchase price per share for THAR stock in Parikh's June 2025 transaction?

The Form 4 filing shows that Director Parikh purchased the THAR shares at a price of $1.45 per share.

Does Sanam Parikh hold any derivative securities of THAR?

Based on Table II of the Form 4 filing, Sanam Parikh did not report holding or transacting in any derivative securities of THAR (such as options, warrants, or convertible securities).

What is Sanam Parikh's role at THAR?

According to the Form 4 filing, Sanam Parikh serves as a Director of Tharimmune, Inc. (THAR) and is not listed as having any other roles such as officer or 10% owner.
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

117.01M
53.96M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER